Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

913 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.
Imai H, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Nakajima T, Takahashi T. Imai H, et al. Among authors: taira t. Med Oncol. 2014 Aug;31(8):88. doi: 10.1007/s12032-014-0088-3. Epub 2014 Jun 25. Med Oncol. 2014. PMID: 24961467 Clinical Trial.
Identification of actionable mutations in malignant pleural mesothelioma.
Shukuya T, Serizawa M, Watanabe M, Akamatsu H, Abe M, Imai H, Tokito T, Ono A, Taira T, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Ohde Y, Nakajima T, Yamamoto N, Koh Y. Shukuya T, et al. Among authors: taira t. Lung Cancer. 2014 Oct;86(1):35-40. doi: 10.1016/j.lungcan.2014.08.004. Epub 2014 Aug 18. Lung Cancer. 2014. PMID: 25174276
The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.
Fujiwara T, Kenmotsu H, Naito T, Kawamura T, Mamesaya N, Kotake M, Kobayashi H, Omori S, Nakashima K, Wakuda K, Ono A, Taira T, Murakami H, Omae K, Mori K, Endo M, Takahashi T. Fujiwara T, et al. Among authors: taira t. Cancer Chemother Pharmacol. 2017 Jun;79(6):1229-1237. doi: 10.1007/s00280-017-3324-7. Epub 2017 Apr 28. Cancer Chemother Pharmacol. 2017. PMID: 28455585
[Anti-VEGF therapy for lung cancer].
Taira T, Yamamoto N. Taira T, et al. Nihon Rinsho. 2012 Dec;70(12):2159-64. Nihon Rinsho. 2012. PMID: 23259390 Review. Japanese.
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T, Taira T, Kenmotsu H, Murakami H, Endo M, Harada H, Takahashi T, Yamamoto N. Akamatsu H, et al. Among authors: taira t. BMC Cancer. 2014 Jan 14;14:18. doi: 10.1186/1471-2407-14-18. BMC Cancer. 2014. PMID: 24422706 Free PMC article.
913 results